SAN DIEGO, Oct. 24, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an
oncology company focused on the clinical development of novel
therapeutics targeting cancer metabolism, announced today that
Charles Baltic, Managing Director and Co-Head of Healthcare at
Needham & Company, has been appointed to its board of
directors. The appointment of Mr. Baltic increases the number of
board members to six and the number of independent directors to
five.
"On behalf of the entire board and management team, I am
delighted to welcome Charles to Marshall
Edwards," said Professor Bryan R.G.
Williams, Chairman of the board of directors. "Charles'
healthcare investment banking experience spans a broad range of
equity, structured, convertible and debt financings in both the
public and private markets, as well as numerous M&A and
advisory assignments. His firsthand knowledge of the capital
markets will be a valuable asset to the company as we continue to
advance our drug candidates along the clinical development
path."
Mr. Baltic has more than 19 years of experience working with
life science and healthcare companies in a significant variety of
transactional contexts. During that time he has been involved in
raising more than $7 billion in life
science financings. Prior to joining Needham in 2009, Mr. Baltic
was a Managing Director and head of the biotechnology practice at
CRT Capital Group. Previously, he served as a Managing Director in
Healthcare Investment Banking at Wachovia Securities, where he
founded and headed its biotechnology practice. Prior to that, he
was with Healthcare Investment Banking at Cowen and Company for six
years, ultimately serving as a Director in life sciences.
Prior to beginning his investment banking career in 1996, Mr.
Baltic practiced corporate and securities law with Dewey Ballantine, representing numerous
healthcare and securities clients. He holds BA and JD degrees from
Georgetown University and an MBA degree
in finance from the Wharton School of the University of Pennsylvania. He is also a founding
Trustee and Current Chair of the Programs Committee of the
non-profit Hope Funds for Cancer Research. Mr. Baltic is a former
Director of Med-Vantage Inc., which was acquired by IMS Health in
2011.
About Marshall Edwards
Marshall Edwards, Inc. (Nasdaq:
MSHL) is a San Diego-based
oncology company focused on the clinical development of novel
anti-cancer therapeutics. The Company's lead programs focus on two
families of small molecules that result in the inhibition of tumor
cell metabolism. The first and most advanced is a NADH oxidase
inhibitor program that includes lead candidate ME-143. The second
is a mitochondrial inhibitor program that includes lead candidate
ME-344. The Company initiated a Phase I clinical trial of
intravenous ME-143 in September 2011
and expects to submit an IND application for ME-344 by the first
quarter of 2012. For more information, please visit
www.marshalledwardsinc.com.
Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical trials and approved by the FDA as
being safe and effective for the intended use. Statements included
in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
SOURCE Marshall Edwards, Inc.